American Renal Associates Holdings Inc (NYSE:ARA) to Post Q2 2018 Earnings of $0.18 Per Share, SunTrust Banks Forecasts

American Renal Associates Holdings Inc (NYSE:ARA) – SunTrust Banks cut their Q2 2018 earnings per share (EPS) estimates for shares of American Renal Associates in a report issued on Wednesday, according to Zacks Investment Research. SunTrust Banks analyst D. Macdonald now expects that the company will post earnings per share of $0.18 for the quarter, down from their previous estimate of $0.19. SunTrust Banks has a “Buy” rating and a $20.00 price objective on the stock. SunTrust Banks also issued estimates for American Renal Associates’ Q3 2018 earnings at $0.19 EPS, Q4 2018 earnings at $0.22 EPS, FY2018 earnings at $0.69 EPS, Q1 2019 earnings at $0.15 EPS, Q2 2019 earnings at $0.21 EPS, Q3 2019 earnings at $0.23 EPS and FY2019 earnings at $0.82 EPS.

A number of other brokerages have also issued reports on ARA. Zacks Investment Research lowered American Renal Associates from a “buy” rating to a “hold” rating in a report on Friday, November 17th. Leerink Swann reissued an “outperform” rating and issued a $17.00 price objective (down previously from $22.00) on shares of American Renal Associates in a research note on Tuesday, November 21st. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $18.25.

American Renal Associates (NYSE:ARA) opened at $18.58 on Friday. The company has a debt-to-equity ratio of 3.57, a quick ratio of 1.13 and a current ratio of 1.16. The stock has a market capitalization of $584.54 and a P/E ratio of -206.44. American Renal Associates has a 12-month low of $9.91 and a 12-month high of $23.30.

American Renal Associates (NYSE:ARA) last released its quarterly earnings results on Tuesday, November 14th. The company reported $0.19 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.16 by $0.03. American Renal Associates had a positive return on equity of 15.80% and a negative net margin of 2.15%. The company had revenue of $187.71 million during the quarter, compared to analyst estimates of $194.60 million. During the same quarter last year, the business posted $0.28 earnings per share. The firm’s revenue was down 2.7% on a year-over-year basis.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Schwab Charles Investment Management Inc. grew its holdings in shares of American Renal Associates by 0.7% during the second quarter. Schwab Charles Investment Management Inc. now owns 39,132 shares of the company’s stock valued at $726,000 after buying an additional 285 shares during the last quarter. Rhumbline Advisers boosted its holdings in American Renal Associates by 2.7% in the second quarter. Rhumbline Advisers now owns 13,383 shares of the company’s stock valued at $248,000 after purchasing an additional 354 shares during the last quarter. Alliancebernstein L.P. boosted its holdings in American Renal Associates by 3.0% in the second quarter. Alliancebernstein L.P. now owns 13,900 shares of the company’s stock valued at $258,000 after purchasing an additional 400 shares during the last quarter. The Manufacturers Life Insurance Company boosted its holdings in American Renal Associates by 19.7% in the second quarter. The Manufacturers Life Insurance Company now owns 8,778 shares of the company’s stock valued at $162,000 after purchasing an additional 1,443 shares during the last quarter. Finally, Teachers Advisors LLC boosted its holdings in American Renal Associates by 8.8% in the second quarter. Teachers Advisors LLC now owns 17,910 shares of the company’s stock valued at $332,000 after purchasing an additional 1,444 shares during the last quarter. 93.27% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “American Renal Associates Holdings Inc (NYSE:ARA) to Post Q2 2018 Earnings of $0.18 Per Share, SunTrust Banks Forecasts” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another site, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/01/14/suntrust-banks-comments-on-american-renal-associates-holdings-incs-q2-2018-earnings-ara.html.

About American Renal Associates

American Renal Associates Holdings, Inc is a dialysis service provider in the United States focused on joint venture (JV) partnerships with physicians. As of December 31, 2016, the Company owned and operated 214 dialysis clinics in partnership with 379 nephrologist partners treating over 14,000 patients in 25 states and the District of Columbia.

Get a free copy of the Zacks research report on American Renal Associates (ARA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for American Renal Associates (NYSE:ARA)

Receive News & Ratings for American Renal Associates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply